Nuvectis intends to use the net proceeds from this offering to continue to advance the development programs of NXP800 and NXP900 or any future product candidate, hiring of additional personnel, ...

GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced ...

Glucot (Nasdaq: GCTK), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced the pricing of a “best efforts” ...

FORT LEE, NJ - Nuvectis Pharma , Inc. (NASDAQ:NVCT), a biopharmaceutical company specializing in precision oncology medicines with a current market capitalization of $131 million, announced today its ...

PHILADELPHIA and VANCOUVER, British Columbia - BriaCell Therapeutics Corp., a clinical-stage biotechnology company specializing in immunotherapies for cancer care, announced today its plans to conduct ...

AUSTIN, Texas--(BUSINESS WIRE)--SailPoint, a leader in unified identity security for enterprises, today announced that it has launched the roadshow for its proposed initial public offering of ...

NEW YORK (AP) — The following is a list of initial public offerings planned for the coming week. Sources include IPO ETF manager Renaissance Capital, and SEC filings. Week of Feb. 3 Titan ...

Akero Therapeutics announced a public offering of over 5.3 million shares at $48 each, aiming for $350 million in proceeds. Akero Therapeutics, Inc. has announced a public offering of 5,333,420 ...

Facebook (FB), now Meta Platforms Inc. (META), went public with its initial public offering (IPO) on May 18, 2012. The popular social networking company had one of the largest and most anticipated ...

In connection with the proposed offering, Immunome expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the public offering.

In addition, Akero intends to grant the underwriters a 30-day option to purchase up to an additional $45.0 million of shares of its common stock at the public offering price, less underwriting ...